Search

Your search keyword '"Minelli R"' showing total 363 results
Start Over Author "Minelli R"
363 results on '"Minelli R"'

5. Association of a CT-based clinical and radiomics score of non-small cell lung cancer (NSCLC) with lymph node status and overall survival

Author

Botta, F, Raimondi, S, Rinaldi, L, Bellerba, F, Corso, F, Bagnardi, V, Origgi, D, Minelli, R, Pitoni, G, Petrella, F, Spaggiari, L, Morganti, A, del Grande, F, Bellomi, M, Rizzo, S, Botta F., Raimondi S., Rinaldi L., Bellerba F., Corso F., Bagnardi V., Origgi D., Minelli R., Pitoni G., Petrella F., Spaggiari L., Morganti A. G., del Grande F., Bellomi M., Rizzo S., Botta, F, Raimondi, S, Rinaldi, L, Bellerba, F, Corso, F, Bagnardi, V, Origgi, D, Minelli, R, Pitoni, G, Petrella, F, Spaggiari, L, Morganti, A, del Grande, F, Bellomi, M, Rizzo, S, Botta F., Raimondi S., Rinaldi L., Bellerba F., Corso F., Bagnardi V., Origgi D., Minelli R., Pitoni G., Petrella F., Spaggiari L., Morganti A. G., del Grande F., Bellomi M., and Rizzo S.

Abstract

Background: To evaluate whether a model based on radiomic and clinical features may be associated with lymph node (LN) status and overall survival (OS) in lung cancer (LC) patients; to evaluate whether CT reconstruction algorithms may influence the model performance. Methods: patients operated on for LC with a pathological stage up to T3N1 were retrospectively selected and divided into training and validation sets. For the prediction of positive LNs and OS, the Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression model was used; univariable and multivariable logistic regression analysis assessed the association of clinicalradiomic variables and endpoints. All tests were repeated after dividing the groups according to the CT reconstruction algorithm. p-values < 0.05 were considered significant. Results: 270 patients were included and divided into training (n = 180) and validation sets (n = 90). Transfissural extension was significantly associated with positive LNs. For OS prediction, high-and low-risk groups were different according to the radiomics score, also after dividing the two groups according to reconstruction algorithms. Conclusions: a combined clinical–radiomics model was not superior to a single clinical or single radiomics model to predict positive LNs. A radiomics model was able to separate high-risk and low-risk patients for OS; CTs reconstructed with Iterative Reconstructions (IR) algorithm showed the best model performance.

Published
2020

11. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort

Author

Iughetti, L., primary, Antoniazzi, F., additional, Giavoli, C., additional, Bona, G., additional, Aversa, T., additional, Greggio, N. A., additional, Guazzarotti, L., additional, Minelli, R., additional, Perrone, L., additional, Persani, L., additional, Pozzobon, G., additional, Ragusa, L., additional, Stagi, S., additional, Tornese, G., additional, Zecchino, C., additional, Gallinari, P., additional, Zouater, H., additional, Fedeli, P., additional, and Zucchini, S., additional

Published
2020
Full Text
View/download PDF

15. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors

Author

Carugo, A., Minelli, R., Sapio, L., Soeung, M., Carbone, F., Robinson, F. S., Tepper, J., Chen, Z., Lovisa, S., Svelto, M., Amin, S., Srinivasan, S., Del Poggetto, E., Loponte, S., Puca, F., Dey, P., Malouf, G. G., Su, X., Li, L., Lopez-Terrada, D., Rakheja, D., Lazar, A. J., Netto, G. J., Rao, P., Sgambato, A., Maitra, A., Tripathi, D. N., Walker, C. L., Karam, J. A., Heffernan, T. P., Viale, A., Roberts, C. W. M., Msaouel, P., Tannir, N. M., Draetta, G. F., Genovese, G., Sgambato A. (ORCID:0000-0002-9487-4563), Genovese G., Carugo, A., Minelli, R., Sapio, L., Soeung, M., Carbone, F., Robinson, F. S., Tepper, J., Chen, Z., Lovisa, S., Svelto, M., Amin, S., Srinivasan, S., Del Poggetto, E., Loponte, S., Puca, F., Dey, P., Malouf, G. G., Su, X., Li, L., Lopez-Terrada, D., Rakheja, D., Lazar, A. J., Netto, G. J., Rao, P., Sgambato, A., Maitra, A., Tripathi, D. N., Walker, C. L., Karam, J. A., Heffernan, T. P., Viale, A., Roberts, C. W. M., Msaouel, P., Tannir, N. M., Draetta, G. F., Genovese, G., Sgambato A. (ORCID:0000-0002-9487-4563), and Genovese G.

Abstract

Alterations in chromatin remodeling genes have been increasingly implicated in human oncogenesis. Specifically, the biallelic inactivation of the SWI/SNF subunit SMARCB1 results in the emergence of extremely aggressive pediatric malignancies. Here, we developed embryonic mosaic mouse models of malignant rhabdoid tumors (MRTs) that faithfully recapitulate the clinical-pathological features of the human disease. We demonstrated that SMARCB1-deficient malignancies exhibit dramatic activation of the unfolded protein response (UPR) and ER stress response via a genetically intact MYC-p19 ARF -p53 axis. As a consequence, these tumors display an exquisite sensitivity to agents inducing proteotoxic stress and inhibition of the autophagic machinery. In conclusion, our findings provide a rationale for drug repositioning trials investigating combinations of agents targeting the UPR and autophagy in SMARCB1-deficient MRTs.

Published
2019

18. Abstracts of the XVIII European Conference on Muscle and Motility: De Blije Werelt, Lunteren, The Netherlands September 12–16, 1989

Author

Nesterov, V. P., Peiper, U., Hiller, J., Krienke, B., Schüttler, K., Szymanski, C., Bottinelli, R., Cappelli, V., Minelli, R., Reggiani, C., Schiaffino, S., Carlhoff, D., D'Haese, J., Dabrowska, R., Nowak, E., Borovikov, Y. S., Cummins, P., Russell, G., McLoughlin, D., Cummins, B., Bonet, A., Harricane, M. C., Audemard, E., Mornet, D., Ropert, S., Cavaillé, F., Redwood, C. S., Bryan, J., Cross, R. A., Kendrick-Jones, J., Marston, S. B., Taggart, M., Marston, S., Makuch, R., Stokarska, G., Dabrowska, R., Cecchi, G., Colomo, F., Poggesi, C., Tesi, C., Puceat, M., Clement, O., Lechene, P., Pelosin, J. -M., Ventura-Clapter, R., Vassort, G., Fischer, W., Pfitzer, G., Ankrett, R. J., Rowe, A. J., Bagshaw, C. R., Perry, S. V., Hebisch, S., Levine, B., Moir, A. J. G., Leszyk, J., Derancourt, J., Patcheil, V., Cavadore, C., Collins, J. H., Swiderek, K., Jaquet, K., Mittmann, K., Meyer, H. E., Heilmeyer, Jr, L. M. J., Travers, F., Barman, T., Duvert, M., Grandier-Vazeille, X., Verna, A., Dan-Goor, M., Mühlrad, A., Muhlrad, A., Polzar, B., Kießling, P., Mannherz, H. G., Lehmann-Klose, S., Gröschel-Stewart, U., Bettache, N., Bertrand, R., Kassab, R., Roulet, A., Cardinaud, R., Harford, J. J., Squire, J. M., Maeda, Y., Chew, M. W. K., Huber, Pia, Schaub, Marcus C., Pierobon-Bormioli, S., Betto, R., Ceoldo, S., Salviati, G., Martinez, I., Ofstad, R., Olsen, R. L., Trinick, J., Barlow, D., Gautel, M., Gibson, T., Labeit, S., Leonard, K., Wardale, J., Whiting, A., Draeger, A., Barth, M., Herzog, M., Gimona, M., Small, J. V., Stelzer, E., Amos, B., Ikebe, M., Bernengo, J. C., Rinne, Bettina, Wray, John S., Poole, K. J. V., Goody, R. S., Thomas, Daniel, Rowe, Arthur, Schröder, R. R., Hofmann, W., Müller, U. C., Menetret, J. -F., Wray, J. S., Lakey, A., Tichelaar, W., Ferguson, C., Bullard, B., Kabsch, W., Pai, E. F., Suck, D., Holmes, K. C., Jarosch, Robert, van Mastrigt, R., Pollack, Gerald H., Horowitz, Arie, Anderl, R., Kuhn, H. J., Burton, K., Jung, D. W. G., Blangé, T., Treijtel, B. W., Bagni, M. A., Garzella, P., Huxley, A. F., Beckers-Bleukx, G., Maréchal, G., Bershitsky, S. Y., Tsaturyan, A. K., Woodward, S. K. A., Eccleston, J. F., Geeves, M. A., Knight, Peter, Fortune, Neil, Geeves, Mike, Arner, A., Arheden, H., Lombardi, V., Piazzesi, G., Stienen, G. J. M., Elzinga, G., de Beer, E. L., van Buuren, K. J. H., ten Kate, Y. J., Grundeman, R. L. F., Schiereck, P., Trombitas, K., Versteeg, P. G. A., Rowe, Arthur J., Bolger, Paul, van der Laarse, W. J., Diegenbach, P. C., Flitney, F. W., Jones, D. A., Hatfaludy, S., Shansky, J., Smiley, B., Vandenburgh, H. H., de Haan, A., Lodder, M. A. N., Berquin, A., Lebacq, J., Curtin, N. A., Woledge, R. C., Hellstrand, P., Lönnbro, P., Wadsö, I., Lammertse, T. S., Zaremba, R., Daut, J., Woledge, R. C., Kushmerick, M. J., McFarland, E., Lyons, G. E., Sassoon, D., Ontell, M., and Buckingham, M. E.

Published
1990
Full Text
View/download PDF

24. THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

Author

Merante, S., Neri, I., Magliacane, D., Fortina, A. Belloni, Ingeborg, F., Pastorello, E. A., Mauro, M., Minelli, R., Difonzo, E. D. Elisa, Guggiari, E., Peserico, A., Romani, I., Bocchia, M., Fontana, E., Di Nuzzo, S., Elli, E. M., Elena, C., Virginia Valeria Ferretti, Brazzelli, V., Ciccocioppo, R., Di Stefano, M., Bossi, G., Boveri, E., Virdi, A., and Triggiani, M.

Published
2015

38. 4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity

Author

Pizzimenti S. 1, Menegatti E. 2, Berardi D. 2, Toaldo C. 1, Pettazzoni P. 1, Minelli R. 1, Giglioni B. 3, Cerbone A. 1, Dianzani M.U. 1, Ferretti C. 4, and Barrera G. 1

Subjects
4-Hydroxynonenal, Caco-2, hTERT gene expression, GSH, HT-29, Telomerase activity, Myc/Mad/Max network
Abstract

The effects of polyunsaturated fatty acids (PUFAs) obtained from the diet on colorectal cancer have been widely explored. However, controversial results have been obtained about the role played by the lipid peroxidation products of PUFAs, such as 4-hydroxy-nonenal (HNE), in the control of colon cancer growth. This aldehyde, indeed, showed both procarcinogenic and protective effects. In an attempt to verify the action of HNE, we studied the effects of a low dose of HNE (1 muM), similar to those "physiologically" found in normal cells and plasma, on telomerase activity, a key parameter of malignant transformation. Caco-2 cells were exposed to HNE and, paralleling cell growth inhibition, we observed the down-regulation of telomerase activity and hTERT expression. Similar effects have also been observed in HT-29 cells, in which HNE inhibited cell proliferation, telomerase activity and hTERT expression, suggesting that the inhibition of telomerase activity could be a general mechanism involved in the antiproliferative effect exerted by this aldehyde. Finally, we elucidated the mechanism of hTERT inhibition by HNE. A reduction of GSH content preceded the decrease of telomerase activity, but this only partially explained the telomerase activity inhibition. The major mechanism of HNE action seems to be the modulation of expression and activity of transcription factors belonging to the Myc/Mad/Max network. Since the presence of PUFAs in the diet exposes epithelial colon cells to HNE, this aldehyde could contribute to cell growth control through the inhibitory action on telomerase activity and hTERT expression, suggesting a protective effect on colon mucosa.

Published
2010

39. Viticultural zoning of Valtellina (Northern Italy)

Author

Murada, G., Failla, O., Mariani, L., Minelli, R., and Scienza, A.

Subjects
Viticulture, Land suitability, Zoning, Settore AGR/03 - Arboricoltura Generale e Coltivazioni Arboree
Published
2006

49. Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy

Author

Minelli R, Girasole G, Pedrazzoni M, Nicola Giuliani, Schianchi C, Giuberti T, Le, Braverman, Salvi M, and Roti E

Subjects
Male, Thyrotoxicosis, Antigens, CD, Interleukin-6, Humans, Interferon-alpha, Female, Receptors, Interleukin, Hyperthyroidism, Receptors, Interleukin-6, Thyroid Diseases, Recombinant Proteins, Hepatitis, Chronic
Abstract

Serum interleukin-6 (IL-6) concentrations are frequently elevated in inflammatory thyroid diseases, such as subacute thyroiditis and amiodarone induced thyroiditis. We and others have recently observed that recombinant interferon-alpha (rIFN-alpha) therapy for chronic, active viral hepatitis and malignant disorders may induce thyroid dysfunction, including thyrotoxicosis secondary to thyroiditis. Serum IL-6 and its soluble receptor (sIL-6R) have been measured for the first time in patients with chronic active hepatitis receiving rIFN-alpha therapy.Studies were carried out in 37 patients treated with rIFN-alpha for chronic, active viral hepatitis. Thyroid function tests and serum IL-6 and sIL-6R were measured before and during rIFN-alpha therapy.Six patients developed inflammatory or destructive thyrotoxicosis confirmed by elevated serum free T4 or free T3 concentrations, suppressed serum thyroid-stimulating hormone (TSH) values, and a low thyroid radioactive iodine uptake. Serum IL-6 and sIL-6R concentrations were not elevated in these patients with rIFN-alpha-induced thyroiditis.These results suggest that serum IL-6 concentrations are not useful in differentiating between inflammatory thyrotoxicosis and hyperthyroidism induced by rIFN-alpha therapy as is the case in amiodarone-induced thyrotoxicosis. It is possible that rIFN-alpha therapy could be associated with an inhibitory effect of rIFN-alpha on the release of IL-6 from damaged thyroid cells and not on the basal secretion of IL-6.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results